|
|
NKT cells in liver diseases |
Shasha Zhu1,2, Huimin Zhang1,2, Li Bai1,2() |
1. CAS Key Laboratory of Innate Immunity and Chronic Disease, CAS Center for Excellence in Molecular Cell Science, School of Life Sciences and Medical Center, University of Science and Technology of China, Hefei 230027, China 2. Innovation Center for Cell Signaling Network, Hefei National Laboratory for Physical Sciences at Microscale, Hefei 230027, China |
|
|
Abstract Natural killer T cells are innate-like and tissue-resident lymphocytes, which recognize lipid antigens and are enriched in the liver. Natural killer T cells play important roles in infections, tumors, autoimmune diseases, and metabolic diseases. In this study, we summarize recent findings on biology of natural killer T cells and their roles in hepatitis B virus and hepatitis C virus infection, autoimmune liver diseases, alcoholic liver disease, nonalcoholic fatty liver disease, and hepatocellular carcinoma. Controversial results from previous studies are discussed, and indicate the dynamic alteration in the role of natural killer T cells during the progression of liver diseases, which might be caused by changes in natural killer T subsets, factors skewing cytokine responses, and intercellular crosstalk between natural killer T cells and CD1d-expressing cells or bystander cells.
|
Keywords
natural killer T cells
hepatitis B virus and hepatitis C virus infection
autoimmune liver diseases
alcoholic liver disease
nonalcoholic fatty liver disease
hepatocellular carcinoma
|
Corresponding Author(s):
Li Bai
|
Just Accepted Date: 09 February 2018
Online First Date: 09 April 2018
Issue Date: 04 May 2018
|
|
1 |
Makino Y, Kanno R, Ito T, Higashino K, Taniguchi M. Predominant expression of invariant Vα14+ TCRα chain in NK1.1+ T cell populations. Int Immunol 1995; 7(7): 1157–1161
https://doi.org/10.1093/intimm/7.7.1157
pmid: 8527413
|
2 |
Beckman EM, Porcelli SA, Morita CT, Behar SM, Furlong ST, Brenner MB. Recognition of a lipid antigen by CD1-restricted αβ+ T cells. Nature 1994; 372(6507): 691–694
https://doi.org/10.1038/372691a0
pmid: 7527500
|
3 |
Godfrey DI, Hammond KJL, Poulton LD, Smyth MJ, Baxter AG. NKT cells: facts, functions and fallacies. Immunol Today 2000; 21(11): 573–583
https://doi.org/10.1016/S0167-5699(00)01735-7
pmid: 11094262
|
4 |
Dascher CC, Brenner MB. Evolutionary constraints on CD1 structure: insights from comparative genomic analysis. Trends Immunol 2003; 24(8): 412–418
https://doi.org/10.1016/S1471-4906(03)00179-0
pmid: 12909453
|
5 |
Godfrey DI, MacDonald HR, Kronenberg M, Smyth MJ, Van Kaer L. NKT cells: what’s in a name? Nat Rev Immunol 2004; 4(3): 231–237
https://doi.org/10.1038/nri1309
pmid: 15039760
|
6 |
Brossay L, Chioda M, Burdin N, Koezuka Y, Casorati G, Dellabona P, Kronenberg M. CD1d-mediated recognition of an α-galactosylceramide by natural killer T cells is highly conserved through mammalian evolution. J Exp Med 1998; 188(8): 1521–1528
https://doi.org/10.1084/jem.188.8.1521
pmid: 9782129
|
7 |
Godfrey DI, Stankovic S, Baxter AG. Raising the NKT cell family. Nat Immunol 2010; 11(3): 197–206
https://doi.org/10.1038/ni.1841
pmid: 20139988
|
8 |
Bendelac A, Savage PB, Teyton L. The biology of NKT cells. Annu Rev Immunol 2007; 25(1): 297–336
https://doi.org/10.1146/annurev.immunol.25.022106.141711
pmid: 17150027
|
9 |
Hammond KJL, Pelikan SB, Crowe NY, Randle-Barrett E, Nakayama T, Taniguchi M, Smyth MJ, van Driel IR, Scollay R, Baxter AG, Godfrey DI. NKT cells are phenotypically and functionally diverse. Eur J Immunol 1999; 29(11): 3768–3781
https://doi.org/10.1002/(SICI)1521-4141(199911)29:11<3768::AID-IMMU3768>3.0.CO;2-G
pmid: 10556834
|
10 |
Akbari O, Stock P, Meyer E, Kronenberg M, Sidobre S, Nakayama T, Taniguchi M, Grusby MJ, DeKruyff RH, Umetsu DT. Essential role of NKT cells producing IL-4 and IL-13 in the development of allergen-induced airway hyperreactivity. Nat Med 2003; 9(5): 582–588
https://doi.org/10.1038/nm851
pmid: 12669034
|
11 |
Sakuishi K, Oki S, Araki M, Porcelli SA, Miyake S, Yamamura T. Invariant NKT cells biased for IL-5 production act as crucial regulators of inflammation. J Immunol 2007; 179(6): 3452–3462
https://doi.org/10.4049/jimmunol.179.6.3452
pmid: 17785779
|
12 |
Cerundolo V, Silk JD, Masri SH, Salio M. Harnessing invariant NKT cells in vaccination strategies. Nat Rev Immunol 2009; 9(1): 28–38
https://doi.org/10.1038/nri2451
pmid: 19079136
|
13 |
Bendelac A, Savage PB, Teyton L. The biology of NKT cells. Annu Rev Immunol 2007; 25(1): 297–336
https://doi.org/10.1146/annurev.immunol.25.022106.141711
pmid: 17150027
|
14 |
Hegde S, Chen X, Keaton JM, Reddington F, Besra GS, Gumperz JE. NKT cells direct monocytes into a DC differentiation pathway. J Leukoc Biol 2007; 81(5): 1224–1235
https://doi.org/10.1189/jlb.1206718
pmid: 17311932
|
15 |
Kitamura H, Ohta A, Sekimoto M, Sato M, Iwakabe K, Nakui M, Yahata T, Meng H, Koda T, Nishimura S, Kawano T, Taniguchi M, Nishimura T. α-Galactosylceramide induces early B-cell activation through IL-4 production by NKT cells. Cell Immunol 2000; 199(1): 37–42
https://doi.org/10.1006/cimm.1999.1602
pmid: 10675273
|
16 |
Hermans IF, Silk JD, Gileadi U, Salio M, Mathew B, Ritter G, Schmidt R, Harris AL, Old L, Cerundolo V. NKT cells enhance CD4+ and CD8+ T cell responses to soluble antigen in vivo through direct interaction with dendritic cells. J Immunol 2003; 171(10): 5140–5147
https://doi.org/10.4049/jimmunol.171.10.5140
pmid: 14607913
|
17 |
Eberl G, MacDonald HR. Selective induction of NK cell proliferation and cytotoxicity by activated NKT cells. Eur J Immunol 2000; 30(4): 985–992
https://doi.org/10.1002/(SICI)1521-4141(200004)30:4<985::AID-IMMU985>3.0.CO;2-E
pmid: 10760785
|
18 |
Kawano T, Cui J, Koezuka Y, Toura I, Kaneko Y, Motoki K, Ueno H, Nakagawa R, Sato H, Kondo E, Koseki H, Taniguchi M. CD1d-restricted and TCR-mediated activation of Vα14 NKT cells by glycosylceramides. Science 1997; 278(5343): 1626–1629
https://doi.org/10.1126/science.278.5343.1626
pmid: 9374463
|
19 |
Godfrey DI, Stankovic S, Baxter AG. Raising the NKT cell family. Nat Immunol 2010; 11(3): 197–206
https://doi.org/10.1038/ni.1841
pmid: 20139988
|
20 |
Godfrey DI, Pellicci DG, Patel O, Kjer-Nielsen L, McCluskey J, Rossjohn J. Antigen recognition by CD1d-restricted NKT T cell receptors. Semin Immunol 2010; 22(2): 61–67
https://doi.org/10.1016/j.smim.2009.10.004
pmid: 19945889
|
21 |
Savage PB, Teyton L, Bendelac A. Glycolipids for natural killer T cells. Chem Soc Rev 2006; 35(9): 771–779
https://doi.org/10.1039/b510638a
pmid: 16936925
|
22 |
Xia C, Yao Q, Schümann J, Rossy E, Chen W, Zhu L, Zhang W, De Libero G, Wang PG. Synthesis and biological evaluation of α-galactosylceramide (KRN7000) and isoglobotrihexosylceramide (iGb3). Bioorg Med Chem Lett 2006; 16(8): 2195–2199
https://doi.org/10.1016/j.bmcl.2006.01.040
pmid: 16458002
|
23 |
Stanic AK, De Silva AD, Park JJ, Sriram V, Ichikawa S, Hirabyashi Y, Hayakawa K, Van Kaer L, Brutkiewicz RR, Joyce S. Defective presentation of the CD1d1-restricted natural Vα14Jα18 NKT lymphocyte antigen caused by β-D-glucosylceramide synthase deficiency. Proc Natl Acad Sci USA 2003; 100(4): 1849–1854
https://doi.org/10.1073/pnas.0430327100
pmid: 12576547
|
24 |
Brigl M, Tatituri RVV, Watts G F M, Bhowruth V, Leadbetter EA, Barton N, Cohen NR, Hsu FF, Besra GS, Brenner MB. Innate and cytokine-driven signals, rather than microbial antigens, dominate in natural killer T cell activation during microbial infection. J Exp Med 2011; 208(6): 1163–1177
https://doi.org/10.1084/jem.20102555
pmid: 21555485
|
25 |
Nagarajan NA, Kronenberg M. Invariant NKT cells amplify the innate immune response to lipopolysaccharide. J Immunol 2007; 178(5): 2706–2713
https://doi.org/10.4049/jimmunol.178.5.2706
pmid: 17312112
|
26 |
Tupin E, Kinjo Y, Kronenberg M. The unique role of natural killer T cells in the response to microorganisms. Nat Rev Microbiol 2007; 5(6): 405–417
https://doi.org/10.1038/nrmicro1657
pmid: 17487145
|
27 |
Paget C, Mallevaey T, Speak AO, Torres D, Fontaine J, Sheehan KCF, Capron M, Ryffel B, Faveeuw C, Leite de Moraes M, Platt F, Trottein F. Activation of invariant NKT cells by toll-like receptor 9-stimulated dendritic cells requires type I interferon and charged glycosphingolipids. Immunity 2007; 27(4): 597–609
https://doi.org/10.1016/j.immuni.2007.08.017
pmid: 17950005
|
28 |
Godfrey DI, Rossjohn J. New ways to turn on NKT cells. J Exp Med 2011; 208(6): 1121–1125
https://doi.org/10.1084/jem.20110983
pmid: 21646400
|
29 |
Hermans IF, Silk JD, Gileadi U, Masri SH, Shepherd D, Farrand KJ, Salio M, Cerundolo V. Dendritic cell function can be modulated through cooperative actions of TLR ligands and invariant NKT cells. J Immunol 2007; 178(5): 2721–2729
https://doi.org/10.4049/jimmunol.178.5.2721
pmid: 17312114
|
30 |
Baxevanis CN, Gritzapis AD, Papamichail M. In vivo antitumor activity of NKT cells activated by the combination of IL-12 and IL-18. J Immunol 2003; 171(6): 2953–2959
https://doi.org/10.4049/jimmunol.171.6.2953
pmid: 12960319
|
31 |
Grela F, Aumeunier A, Bardel E, Van LP, Bourgeois E, Vanoirbeek J, Leite-de-Moraes M, Schneider E, Dy M, Herbelin A, Thieblemont N. The TLR7 agonist R848 alleviates allergic inflammation by targeting invariant NKT cells to produce IFN-γ. J Immunol 2011; 186(1): 284–290
https://doi.org/10.4049/jimmunol.1001348
pmid: 21131420
|
32 |
Miyamoto K, Miyake S, Yamamura T. A synthetic glycolipid prevents autoimmune encephalomyelitis by inducing TH2 bias of natural killer T cells. Nature 2001; 413(6855): 531–534
https://doi.org/10.1038/35097097
pmid: 11586362
|
33 |
Yu KOA, Im JS, Molano A, Dutronc Y, Illarionov PA, Forestier C, Fujiwara N, Arias I, Miyake S, Yamamura T, Chang YT, Besra GS, Porcelli SA. Modulation of CD1d-restricted NKT cell responses by using N-acyl variants of α-galactosylceramides. Proc Natl Acad Sci USA 2005; 102(9): 3383–3388
https://doi.org/10.1073/pnas.0407488102
pmid: 15722411
|
34 |
Goff RD, Gao Y, Mattner J, Zhou D, Yin N, Cantu C 3rd, Teyton L, Bendelac A, Savage PB. Effects of lipid chain lengths in α-galactosylceramides on cytokine release by natural killer T cells. J Am Chem Soc 2004; 126(42): 13602–13603
https://doi.org/10.1021/ja045385q
pmid: 15493902
|
35 |
McCarthy C, Shepherd D, Fleire S, Stronge VS, Koch M, Illarionov PA, Bossi G, Salio M, Denkberg G, Reddington F, Tarlton A, Reddy BG, Schmidt RR, Reiter Y, Griffiths GM, van der Merwe PA, Besra GS, Jones EY, Batista FD, Cerundolo V. The length of lipids bound to human CD1d molecules modulates the affinity of NKT cell TCR and the threshold of NKT cell activation. J Exp Med 2007; 204(5): 1131–1144
https://doi.org/10.1084/jem.20062342
pmid: 17485514
|
36 |
Bai L, Constantinides MG, Thomas SY, Reboulet R, Meng F, Koentgen F, Teyton L, Savage PB, Bendelac A. Distinct APCs explain the cytokine bias of α-galactosylceramide variants in vivo. J Immunol 2012; 188(7): 3053–3061
https://doi.org/10.4049/jimmunol.1102414
pmid: 22393151
|
37 |
Oki S, Chiba A, Yamamura T, Miyake S. The clinical implication and molecular mechanism of preferential IL-4 production by modified glycolipid-stimulated NKT cells. J Clin Invest 2004; 113(11): 1631–1640
https://doi.org/10.1172/JCI200420862
pmid: 15173890
|
38 |
Hua J, Ma X, Webb T, Potter JJ, Oelke M, Li Z. Dietary fatty acids modulate antigen presentation to hepatic NKT cells in nonalcoholic fatty liver disease. J Lipid Res 2010; 51(7): 1696–1703
https://doi.org/10.1194/jlr.M003004
pmid: 20185414
|
39 |
Xie D, Zhu S, Bai L. Lactic acid in tumor microenvironments causes dysfunction of NKT cells by interfering with mTOR signaling. Sci China Life Sci 2016; 59(12): 1290–1296
https://doi.org/10.1007/s11427-016-0348-7
pmid: 27995420
|
40 |
Apostolou I, Takahama Y, Belmant C, Kawano T, Huerre M, Marchal G, Cui J, Taniguchi M, Nakauchi H, Fournie JJ, Kourilsky P, Gachelin G. Murine natural killer T (NKT) cells contribute to the granulomatous reaction caused by mycobacterial cell walls. Proc Natl Acad Sci USA 1999; 96(9): 5141–5146
https://doi.org/10.1073/pnas.96.9.5141
pmid: 10220432
|
41 |
Chackerian A, Alt J, Perera V, Behar SM. Activation of NKT cells protects mice from tuberculosis. Infect Immun 2002; 70(11): 6302–6309
https://doi.org/10.1128/IAI.70.11.6302-6309.2002
pmid: 12379709
|
42 |
Opasawatchai A, Matangkasombut P. iNKT cells and their potential lipid ligands during viral infection. Front Immunol 2015; 6: 378
https://doi.org/10.3389/fimmu.2015.00378
pmid: 26257744
|
43 |
Tahir SM, Cheng O, Shaulov A, Koezuka Y, Bubley GJ, Wilson SB, Balk SP, Exley MA. Loss of IFN-γ production by invariant NK T cells in advanced cancer. J Immunol 2001; 167(7): 4046–4050
https://doi.org/10.4049/jimmunol.167.7.4046
pmid: 11564825
|
44 |
Toura I, Kawano T, Akutsu Y, Nakayama T, Ochiai T, Taniguchi M. Cutting edge: inhibition of experimental tumor metastasis by dendritic cells pulsed with α-galactosylceramide. J Immunol 1999; 163(5): 2387–2391
pmid: 10452972
|
45 |
Miyamoto K, Miyake S, Yamamura T. A synthetic glycolipid prevents autoimmune encephalomyelitis by inducing TH2 bias of natural killer T cells. Nature 2001; 413(6855): 531–534
https://doi.org/10.1038/35097097
pmid: 11586362
|
46 |
Singh AK, Wilson MT, Hong S, Olivares-Villagómez D, Du C, Stanic AK, Joyce S, Sriram S, Koezuka Y, Van Kaer L. Natural killer T cell activation protects mice against experimental autoimmune encephalomyelitis. J Exp Med 2001; 194(12): 1801–1811
https://doi.org/10.1084/jem.194.12.1801
pmid: 11748281
|
47 |
Zhang H, Xue R, Zhu S, Fu S, Chen Z, Zhou R, Tian Z, Bai L. M2-specific reduction of CD1d switches NKT cell-mediated immune responses and triggers metaflammation in adipose tissue. Cell Mol Immunol 2017 Apr 10. [Epub ahead of print] https://doi.org/10.1038/cmi.2017.11
https://doi.org/10.1038/cmi.2017.11
pmid: 28392574
|
48 |
Thomas SY, Scanlon ST, Griewank KG, Constantinides MG, Savage AK, Barr KA, Meng F, Luster AD, Bendelac A. PLZF induces an intravascular surveillance program mediated by long-lived LFA-1-ICAM-1 interactions. J Exp Med 2011; 208(6): 1179–1188
https://doi.org/10.1084/jem.20102630
pmid: 21624939
|
49 |
Slauenwhite D, Johnston B. Regulation of NKT cell localization in homeostasis and infection. Front Immunol 2015; 6: 255
https://doi.org/10.3389/fimmu.2015.00255
pmid: 26074921
|
50 |
Geissmann F, Cameron TO, Sidobre S, Manlongat N, Kronenberg M, Briskin MJ, Dustin ML, Littman DR. Intravascular immune surveillance by CXCR6+ NKT cells patrolling liver sinusoids. PLoS Biol 2005; 3(4): e113
https://doi.org/10.1371/journal.pbio.0030113
pmid: 15799695
|
51 |
King IL, Amiel E, Tighe M, Mohrs K, Veerapen N, Besra G, Mohrs M, Leadbetter EA. The mechanism of splenic invariant NKT cell activation dictates localization in vivo. J Immunol 2013; 191(2): 572–582
https://doi.org/10.4049/jimmunol.1300299
pmid: 23785119
|
52 |
Barral P, Sánchez-Niño MD, van Rooijen N, Cerundolo V, Batista FD. The location of splenic NKT cells favours their rapid activation by blood-borne antigen. EMBO J 2012; 31(10): 2378–2390
https://doi.org/10.1038/emboj.2012.87
pmid: 22505026
|
53 |
Lynch L, Michelet X, Zhang S, Brennan PJ, Moseman A, Lester C, Besra G, Vomhof-Dekrey EE, Tighe M, Koay HF, Godfrey DI, Leadbetter EA, Sant’Angelo DB, von Andrian U, Brenner MB. Regulatory iNKT cells lack expression of the transcription factor PLZF and control the homeostasis of T(reg) cells and macrophages in adipose tissue. Nat Immunol 2015; 16(1): 85–95
https://doi.org/10.1038/ni.3047
pmid: 25436972
|
54 |
Scanlon ST, Thomas SY, Ferreira CM, Bai L, Krausz T, Savage PB, Bendelac A. Airborne lipid antigens mobilize resident intravascular NKT cells to induce allergic airway inflammation. J Exp Med 2011; 208(10): 2113–2124
https://doi.org/10.1084/jem.20110522
pmid: 21930768
|
55 |
Constantinides MG, Bendelac A. Transcriptional regulation of the NKT cell lineage. Curr Opin Immunol 2013; 25(2): 161–167
https://doi.org/10.1016/j.coi.2013.01.003
pmid: 23402834
|
56 |
Doisne JM, Becourt C, Amniai L, Duarte N, Le Luduec JB, Eberl G, Benlagha K. Skin and peripheral lymph node invariant NKT cells are mainly retinoic acid receptor-related orphan receptor γt+ and respond preferentially under inflammatory conditions. J Immunol 2009; 183(3): 2142–2149
https://doi.org/10.4049/jimmunol.0901059
pmid: 19587013
|
57 |
Gapin L. Development of invariant natural killer T cells. Curr Opin Immunol 2016; 39: 68–74
https://doi.org/10.1016/j.coi.2016.01.001
pmid: 26802287
|
58 |
Kim EY, Lynch L, Brennan PJ, Cohen NR, Brenner MB. The transcriptional programs of iNKT cells. Semin Immunol 2015; 27(1): 26–32
https://doi.org/10.1016/j.smim.2015.02.005
pmid: 25841627
|
59 |
Scanlon ST, Thomas SY, Ferreira CM, Bai L, Krausz T, Savage PB, Bendelac A. Airborne lipid antigens mobilize resident intravascular NKT cells to induce allergic airway inflammation. J Exp Med 2011; 208(10): 2113–2124
https://doi.org/10.1084/jem.20110522
pmid: 21930768
|
60 |
Terashima A, Watarai H, Inoue S, Sekine E, Nakagawa R, Hase K, Iwamura C, Nakajima H, Nakayama T, Taniguchi M. A novel subset of mouse NKT cells bearing the IL-17 receptor B responds to IL-25 and contributes to airway hyperreactivity. J Exp Med 2008; 205(12): 2727–2733
https://doi.org/10.1084/jem.20080698
pmid: 19015310
|
61 |
Yoshiga Y, Goto D, Segawa S, Ohnishi Y, Matsumoto I, Ito S, Tsutsumi A, Taniguchi M, Sumida T. Invariant NKT cells produce IL-17 through IL-23-dependent and -independent pathways with potential modulation of Th17 response in collagen-induced arthritis. Int J Mol Med 2008; 22(3): 369–374
pmid: 18698497
|
62 |
Pichavant M, Goya S, Meyer EH, Johnston RA, Kim HY, Matangkasombut P, Zhu M, Iwakura Y, Savage PB, DeKruyff RH, Shore SA, Umetsu DT. Ozone exposure in a mouse model induces airway hyperreactivity that requires the presence of natural killer T cells and IL-17. J Exp Med 2008; 205(2): 385–393
https://doi.org/10.1084/jem.20071507
pmid: 18250191
|
63 |
Michel ML, Keller AC, Paget C, Fujio M, Trottein F, Savage PB, Wong CH, Schneider E, Dy M, Leite-de-Moraes MC. Identification of an IL-17-producing NK1.1(neg) iNKT cell population involved in airway neutrophilia. J Exp Med 2007; 204(5): 995–1001
https://doi.org/10.1084/jem.20061551
pmid: 17470641
|
64 |
Sag D, Krause P, Hedrick CC, Kronenberg M, Wingender G. IL-10-producing NKT10 cells are a distinct regulatory invariant NKT cell subset. J Clin Invest 2014; 124(9): 3725–3740
https://doi.org/10.1172/JCI72308
pmid: 25061873
|
65 |
Dashtsoodol N, Shigeura T, Aihara M, Ozawa R, Kojo S, Harada M, Endo TA, Watanabe T, Ohara O, Taniguchi M. Alternative pathway for the development of Vα14+ NKT cells directly from CD4−CD8− thymocytes that bypasses the CD4+CD8+ stage. Nat Immunol 2017; 18(3): 274–282
https://doi.org/10.1038/ni.3668
pmid: 28135253
|
66 |
Lee PT, Benlagha K, Teyton L, Bendelac A. Distinct functional lineages of human Vα24 natural killer T cells. J Exp Med 2002; 195(5): 637–641
https://doi.org/10.1084/jem.20011908
pmid: 11877486
|
67 |
Doherty G, Golden-Mason L. NKT cells from normal and tumor-bearing human livers are phenotypically and functionally distinct from murine NKT cells. J Immunol 2003; 171(10): 1775–1779 PMID:12902477
https://doi.org/10.4049/jimmunol.171.10.5631
|
68 |
Brennan PJ, Brigl M, Brenner MB. Invariant natural killer T cells: an innate activation scheme linked to diverse effector functions. Nat Rev Immunol 2013; 13(2): 101–117
https://doi.org/10.1038/nri3369
pmid: 23334244
|
69 |
O’Reilly V, Zeng SG, Bricard G, Atzberger A, Hogan AE, Jackson J, Feighery C, Porcelli SA, Doherty DG. Distinct and overlapping effector functions of expanded human CD4+, CD8+ and CD4−CD8− invariant natural killer T cells. PLoS One 2011; 6(12): e28648
https://doi.org/10.1371/journal.pone.0028648
pmid: 22174854
|
70 |
Bandyopadhyay K, Marrero I, Kumar V. NKT cell subsets as key participants in liver physiology and pathology. Cell Mol Immunol 2016; 13(3): 337–346
https://doi.org/10.1038/cmi.2015.115
pmid: 26972772
|
71 |
Gao B. Basic liver immunology. Cell Mol Immunol 2016; 13(3): 265–266
https://doi.org/10.1038/cmi.2016.09
pmid: 27041634
|
72 |
Lan P, Fan Y, Zhao Y, Lou X, Monsour HP, Zhang X, Choi Y, Dou Y, Ishii N, Ghobrial RM, Xiao X, Li XC. TNF superfamily receptor OX40 triggers invariant NKT cell pyroptosis and liver injury. J Clin Invest 2017; 127(6): 2222–2234
https://doi.org/10.1172/JCI91075
pmid: 28436935
|
73 |
Fahey S, Dempsey E, Long A. The role of chemokines in acute and chronic hepatitis C infection. Cell Mol Immunol 2014; 11(1): 25–40
https://doi.org/10.1038/cmi.2013.37
pmid: 23954947
|
74 |
Wang X, Dong A, Xiao J, Zhou X, Mi H, Xu H, Zhang J, Wang B. Overcoming HBV immune tolerance to eliminate HBsAg-positive hepatocytes via pre-administration of GM-CSF as a novel adjuvant for a hepatitis B vaccine in HBV transgenic mice. Cell Mol Immunol 2016; 13(6): 850–861
https://doi.org/10.1038/cmi.2015.64
pmid: 26166767
|
75 |
Yang Y, Han Q, Hou Z, Zhang C, Tian Z, Zhang J. Exosomes mediate hepatitis B virus (HBV) transmission and NK-cell dysfunction. Cell Mol Immunol 2017; 14(5): 465–475
pmid: 27238466
|
76 |
Guidotti LG, Chisari FV. Immunobiology and pathogenesis of viral hepatitis. Annu Rev Pathol 2006; 1(1): 23–61
https://doi.org/10.1146/annurev.pathol.1.110304.100230
pmid: 18039107
|
77 |
Huang LM, Lu CY, Chen DS. Hepatitis B virus infection, its sequelae, and prevention by vaccination. Curr Opin Immunol 2011; 23(2): 237–243
https://doi.org/10.1016/j.coi.2010.12.013
pmid: 21257300
|
78 |
Guy CS, Mulrooney-Cousins PM, Churchill ND, Michalak TI. Intrahepatic expression of genes affiliated with innate and adaptive immune responses immediately after invasion and during acute infection with woodchuck hepadnavirus. J Virol 2008; 82(17): 8579–8591
https://doi.org/10.1128/JVI.01022-08
pmid: 18596101
|
79 |
Fisicaro P, Valdatta C, Boni C, Massari M, Mori C, Zerbini A, Orlandini A, Sacchelli L, Missale G, Ferrari C. Early kinetics of innate and adaptive immune responses during hepatitis B virus infection. Gut 2009; 58(7): 974–982
https://doi.org/10.1136/gut.2008.163600
pmid: 19201769
|
80 |
Webster GJ, Reignat S, Maini MK, Whalley SA, Ogg GS, King A, Brown D, Amlot PL, Williams R, Vergani D, Dusheiko GM, Bertoletti A. Incubation phase of acute hepatitis B in man: dynamic of cellular immune mechanisms. Hepatology 2000; 32(5): 1117–1124
https://doi.org/10.1053/jhep.2000.19324
pmid: 11050064
|
81 |
Jiang X, Zhang M, Lai Q, Huang X, Li Y, Sun J, Abbott WG, Ma S, Hou J. Restored circulating invariant NKT cells are associated with viral control in patients with chronic hepatitis B. PLoS One 2011; 6(12): e28871
https://doi.org/10.1371/journal.pone.0028871
pmid: 22194934
|
82 |
de Lalla C, Galli G, Aldrighetti L, Romeo R, Mariani M, Monno A, Nuti S, Colombo M, Callea F, Porcelli SA, Panina-Bordignon P, Abrignani S, Casorati G, Dellabona P. Production of profibrotic cytokines by invariant NKT cells characterizes cirrhosis progression in chronic viral hepatitis. J Immunol 2004; 173(2): 1417–1425
https://doi.org/10.4049/jimmunol.173.2.1417
pmid: 15240738
|
83 |
Zhu H, Zhang Y, Liu H, Zhang Y, Kang Y, Mao R, Yang F, Zhou D, Zhang J. Preserved function of circulating invariant natural killer T cells in patients with chronic hepatitis B virus infection. Medicine (Baltimore) 2015; 94(24): e961
https://doi.org/10.1097/MD.0000000000000961
pmid: 26091463
|
84 |
Ito H, Ando K, Ishikawa T, Nakayama T, Taniguchi M, Saito K, Imawari M, Moriwaki H, Yokochi T, Kakumu S, Seishima M. Role of Vα14+ NKT cells in the development of hepatitis B virus-specific CTL: activation of Vα14+ NKT cells promotes the breakage of CTL tolerance. Int Immunol 2008; 20(7): 869–879
https://doi.org/10.1093/intimm/dxn046
pmid: 18487227
|
85 |
Kakimi K, Guidotti LG, Koezuka Y, Chisari FV. Natural killer T cell activation inhibits hepatitis B virus replication in vivo. J Exp Med 2000; 192(7): 921–930
https://doi.org/10.1084/jem.192.7.921
pmid: 11015434
|
86 |
Zeissig S, Murata K, Sweet L, Publicover J, Hu Z, Kaser A, Bosse E, Iqbal J, Hussain MM, Balschun K, Röcken C, Arlt A, Günther R, Hampe J, Schreiber S, Baron JL, Moody DB, Liang TJ, Blumberg RS. Hepatitis B virus-induced lipid alterations contribute to natural killer T cell-dependent protective immunity. Nat Med 2012; 18(7): 1060–1068
https://doi.org/10.1038/nm.2811
pmid: 22706385
|
87 |
Woltman AM, Ter Borg MJ, Binda RS, Sprengers D, von Blomberg BM, Scheper RJ, Hayashi K, Nishi N, Boonstra A, van der Molen R, Janssen HL. α-Galactosylceramide in chronic hepatitis B infection: results from a randomized placebo-controlled Phase I/II trial. Antivir Ther 2009; 14(6): 809–818
https://doi.org/10.3851/IMP1295
pmid: 19812443
|
88 |
van der Vliet HJ, Molling JW, von Blomberg BM, Kölgen W, Stam AG, de Gruijl TD, Mulder CJ, Janssen HL, Nishi N, van den Eertwegh AJ, Scheper RJ, van Nieuwkerk CJ. Circulating Vα24+Vβ11+ NKT cell numbers and dendritic cell CD1d expression in hepatitis C virus infected patients. Clin Immunol 2005; 114(2): 183–189
https://doi.org/10.1016/j.clim.2004.10.001
pmid: 15639652
|
89 |
Inoue M, Kanto T, Miyatake H, Itose I, Miyazaki M, Yakushijin T, Sakakibara M, Kuzushita N, Hiramatsu N, Takehara T, Kasahara A, Hayashi N. Enhanced ability of peripheral invariant natural killer T cells to produce IL-13 in chronic hepatitis C virus infection. J Hepatol 2006; 45(2): 190–196
https://doi.org/10.1016/j.jhep.2006.01.034
pmid: 16580086
|
90 |
Deignan T, Curry MP, Doherty DG, Golden-Mason L, Volkov Y, Norris S, Nolan N, Traynor O, McEntee G, Hegarty JE, O’Farrelly C. Decrease in hepatic CD56+ T cells and Vα24+ natural killer T cells in chronic hepatitis C viral infection. J Hepatol 2002; 37(1): 101–108
https://doi.org/10.1016/S0168-8278(02)00072-7
pmid: 12076868
|
91 |
Lucas M, Gadola S, Meier U, Young NT, Harcourt G, Karadimitris A, Coumi N, Brown D, Dusheiko G, Cerundolo V, Klenerman P. Frequency and phenotype of circulating Vα24/Vβ11 double-positive natural killer T cells during hepatitis C virus infection. J Virol 2003; 77(3): 2251–2257
https://doi.org/10.1128/JVI.77.3.2251-2257.2003
pmid: 12525661
|
92 |
Werner JM, Heller T, Gordon AM, Sheets A, Sherker AH, Kessler E, Bean KS, Stevens M, Schmitt J, Rehermann B. Innate immune responses in hepatitis C virus-exposed healthcare workers who do not develop acute infection. Hepatology 2013; 58(5): 1621–1631
https://doi.org/10.1002/hep.26353
pmid: 23463364
|
93 |
Miyaki E, Hiraga N, Imamura M, Uchida T, Kan H, Tsuge M, Abe-Chayama H, Hayes CN, Makokha GN, Serikawa M, Aikata H, Ochi H, Ishida Y, Tateno C, Ohdan H, Chayama K. Interferon α treatment stimulates interferon γ expression in type I NKT cells and enhances their antiviral effect against hepatitis C virus. PLoS One 2017; 12(3): e0172412
https://doi.org/10.1371/journal.pone.0172412
pmid: 28253324
|
94 |
Exley MA, He Q, Cheng O, Wang RJ, Cheney CP, Balk SP, Koziel MJ. Cutting edge: compartmentalization of Th1-like noninvariant CD1d-reactive T cells in hepatitis C virus-infected liver. J Immunol 2002; 168(4): 1519–1523
https://doi.org/10.4049/jimmunol.168.4.1519
pmid: 11823474
|
95 |
Durante-Mangoni E, Wang R, Shaulov A, He Q, Nasser I, Afdhal N, Koziel MJ, Exley MA. Hepatic CD1d expression in hepatitis C virus infection and recognition by resident proinflammatory CD1d-reactive T cells. J Immunol 2004; 173(3): 2159–2166
https://doi.org/10.4049/jimmunol.173.3.2159
pmid: 15265953
|
96 |
Li M, Zhou ZH, Sun XH, Zhang X, Zhu XJ, Jin SG, Jiang Y, Gao YT, Li CZ, Gao YQ. The dynamic changes of circulating invariant natural killer T cells during chronic hepatitis B virus infection. Hepatol Int 2016; 10(4): 594–601
https://doi.org/10.1007/s12072-015-9650-0
pmid: 26924524
|
97 |
Wang H, Feng D, Park O, Yin S, Gao B. Invariant NKT cell activation induces neutrophil accumulation and hepatitis: opposite regulation by IL-4 and IFN-g. Hepatology 2013; 58(4): 1474–1485
https://doi.org/10.1002/hep.26471
pmid: 23686838
|
98 |
Hirschfield GM, Heathcote EJ, Gershwin ME. Pathogenesis of cholestatic liver disease and therapeutic approaches. Gastroenterology 2010; 139(5): 1481–1496
https://doi.org/10.1053/j.gastro.2010.09.004
pmid: 20849855
|
99 |
Liaskou E, Hirschfield GM, Gershwin ME. Mechanisms of tissue injury in autoimmune liver diseases. Semin Immunopathol 2014; 36(5): 553–568
https://doi.org/10.1007/s00281-014-0439-3
pmid: 25082647
|
100 |
Kita H, Naidenko OV, Kronenberg M, Ansari AA, Rogers P, He XS, Koning F, Mikayama T, Van De Water J, Coppel RL, Kaplan M, Gershwin ME. Quantitation and phenotypic analysis of natural killer T cells in primary biliary cirrhosis using a human CD1d tetramer. Gastroenterology 2002; 123(4): 1031–1043
https://doi.org/10.1053/gast.2002.36020
pmid: 12360465
|
101 |
Tsuneyama K, Yasoshima M, Harada K, Hiramatsu K, Gershwin ME, Nakanuma Y. Increased CD1d expression on small bile duct epithelium and epithelioid granuloma in livers in primary biliary cirrhosis. Hepatology 1998; 28(3): 620–623
https://doi.org/10.1002/hep.510280303
pmid: 9731549
|
102 |
Sebode M, Schramm C. Natural killer T cells: novel players in biliary disease? Hepatology 2015; 62(4): 999–1000
https://doi.org/10.1002/hep.27862
pmid: 25914184
|
103 |
Chuang YH, Lian ZX, Yang GX, Shu SA, Moritoki Y, Ridgway WM, Ansari AA, Kronenberg M, Flavell RA, Gao B, Gershwin ME. Natural killer T cells exacerbate liver injury in a transforming growth factor beta receptor II dominant-negative mouse model of primary biliary cirrhosis. Hepatology 2008; 47(2): 571–580
https://doi.org/10.1002/hep.22052
pmid: 18098320
|
104 |
Olszak T, Neves JF, Dowds CM, Baker K, Glickman J, Davidson NO, Lin CS, Jobin C, Brand S, Sotlar K, Wada K, Katayama K, Nakajima A, Mizuguchi H, Kawasaki K, Nagata K, Müller W, Snapper SB, Schreiber S, Kaser A, Zeissig S, Blumberg RS. Protective mucosal immunity mediated by epithelial CD1d and IL-10. Nature 2014; 509(7501): 497–502
https://doi.org/10.1038/nature13150
pmid: 24717441
|
105 |
Wu SJ, Yang YH, Tsuneyama K, Leung PSC, Illarionov P, Gershwin ME, Chuang YH. Innate immunity and primary biliary cirrhosis: activated invariant natural killer T cells exacerbate murine autoimmune cholangitis and fibrosis. Hepatology 2011; 53(3): 915–925
https://doi.org/10.1002/hep.24113
pmid: 21374662
|
106 |
Mattner J, Savage PB, Leung P, Oertelt SS, Wang V, Trivedi O, Scanlon ST, Pendem K, Teyton L, Hart J, Ridgway WM, Wicker LS, Gershwin ME, Bendelac A. Liver autoimmunity triggered by microbial activation of natural killer T cells. Cell Host Microbe 2008; 3(5): 304–315
https://doi.org/10.1016/j.chom.2008.03.009
pmid: 18474357
|
107 |
O’Shea RS, Dasarathy S, McCullough AJ. Alcoholic liver disease. Am J Gastroenterol 2010; 105(1): 14–32, quiz 33
https://doi.org/10.1038/ajg.2009.593
pmid: 19904248
|
108 |
Beier JI, McClain CJ. Mechanisms and cell signaling in alcoholic liver disease. Biol Chem 2010; 391(11): 1249–1264
https://doi.org/10.1515/bc.2010.137
pmid: 20868231
|
109 |
Kono H, Rusyn I, Yin M, Gäbele E, Yamashina S, Dikalova A, Kadiiska MB, Connor HD, Mason RP, Segal BH, Bradford BU, Holland SM, Thurman RG. NADPH oxidase-derived free radicals are key oxidants in alcohol-induced liver disease. J Clin Invest 2000; 106(7): 867–872
https://doi.org/10.1172/JCI9020
pmid: 11018074
|
110 |
Laso FJ, Vaquero JM, Almeida J, Marcos M, Orfao A. Chronic alcohol consumption is associated with changes in the distribution, immunophenotype, and the inflammatory cytokine secretion profile of circulating dendritic cells. Alcohol Clin Exp Res 2007; 31(5): 846–854
https://doi.org/10.1111/j.1530-0277.2007.00377.x
pmid: 17386065
|
111 |
Lau AH, Abe M, Thomson AW. Ethanol affects the generation, cosignaling molecule expression, and function of plasmacytoid and myeloid dendritic cell subsets in vitro and in vivo. J Leukoc Biol 2006; 79(5): 941–953
https://doi.org/10.1189/jlb.0905517
pmid: 16478920
|
112 |
Stadlbauer V, Mookerjee RP, Wright GA, Davies NA, Jürgens G, Hallström S, Jalan R. Role of Toll-like receptors 2, 4, and 9 in mediating neutrophil dysfunction in alcoholic hepatitis. Am J Physiol Gastrointest Liver Physiol 2009; 296(1): G15–G22
https://doi.org/10.1152/ajpgi.90512.2008
pmid: 19033535
|
113 |
Zhang H, Meadows GG. Chronic alcohol consumption in mice increases the proportion of peripheral memory T cells by homeostatic proliferation. J Leukoc Biol 2005; 78(5): 1070–1080
https://doi.org/10.1189/jlb.0605317
pmid: 16260584
|
114 |
Lemmers A, Moreno C, Gustot T, Maréchal R, Degré D, Demetter P, de Nadai P, Geerts A, Quertinmont E, Vercruysse V, Le Moine O, Devière J. The interleukin-17 pathway is involved in human alcoholic liver disease. Hepatology 2009; 49(2): 646–657
https://doi.org/10.1002/hep.22680
pmid: 19177575
|
115 |
Minagawa M, Deng Q, Liu ZX, Tsukamoto H, Dennert G. Activated natural killer T cells induce liver injury by Fas and tumor necrosis factor-α during alcohol consumption. Gastroenterology 2004; 126(5): 1387–1399
https://doi.org/10.1053/j.gastro.2004.01.022
pmid: 15131799
|
116 |
Mathews S, Feng D, Maricic I, Ju C, Kumar V, Gao B. Invariant natural killer T cells contribute to chronic-plus-binge ethanol-mediated liver injury by promoting hepatic neutrophil infiltration. Cell Mol Immunol 2016; 13(2): 206–216
https://doi.org/10.1038/cmi.2015.06
pmid: 25661730
|
117 |
Maricic I, Sheng H, Marrero I, Seki E, Kisseleva T, Chaturvedi S, Molle N, Mathews SA, Gao B, Kumar V. Inhibition of type I natural killer T cells by retinoids or following sulfatide-mediated activation of type II natural killer T cells attenuates alcoholic liver disease in mice. Hepatology 2015; 61(4): 1357–1369
https://doi.org/10.1002/hep.27632
pmid: 25477000
|
118 |
Buschard K, Hansen AK, Jensen K, Lindenbergh-Kortleve DJ, de Ruiter LF, Krohn TC, Hufeldt MR, Vogensen FK, Aasted B, Osterbye T, Roep BO, de Haar C, Nieuwenhuis EE. Alcohol facilitates CD1d loading, subsequent activation of NKT cells, and reduces the incidence of diabetes in NOD mice. PLoS One 2011; 6(4): e17931
https://doi.org/10.1371/journal.pone.0017931
pmid: 21483778
|
119 |
Cui K, Yan G, Xu C, Chen Y, Wang J, Zhou R, Bai L, Lian Z, Wei H, Sun R, Tian Z. Invariant NKT cells promote alcohol-induced steatohepatitis through interleukin-1β in mice. J Hepatol 2015; 62(6): 1311–1318
https://doi.org/10.1016/j.jhep.2014.12.027
pmid: 25582105
|
120 |
Bertola A, Park O, Gao B. Chronic plus binge ethanol feeding synergistically induces neutrophil infiltration and liver injury in mice: a critical role for E-selectin. Hepatology 2013; 58(5): 1814–1823
https://doi.org/10.1002/hep.26419
pmid: 23532958
|
121 |
Jeong D, Ahn S, Oh S J, Ahn J Y, Lee S H, Chung D H. GM-CSF and IL-4 produced by NKT cells inversely regulate IL-1β production by macrophages. J Immunol 2014; 192
|
122 |
Mikolasevic I, Milic S, Turk Wensveen T, Grgic I, Jakopcic I, Stimac D, Wensveen F, Orlic L. Nonalcoholic fatty liver disease — a multisystem disease? World J Gastroenterol 2016; 22(43): 9488–9505
https://doi.org/10.3748/wjg.v22.i43.9488
pmid: 27920470
|
123 |
Hart KM, Fabre T, Sciurba JC, Gieseck RL 3rd, Borthwick LA, Vannella KM, Acciani TH, de Queiroz Prado R, Thompson RW, White S, Soucy G, Bilodeau M, Ramalingam TR, Arron JR, Shoukry NH, Wynn TA. Type 2 immunity is protective in metabolic disease but exacerbates NAFLD collaboratively with TGF-β. Sci Transl Med 2017; 9(396): eaal3694
https://doi.org/10.1126/scitranslmed.aal3694
pmid: 28659437
|
124 |
Parekh S, Anania FA. Abnormal lipid and glucose metabolism in obesity: implications for nonalcoholic fatty liver disease. Gastroenterology 2007; 132(6): 2191–2207
https://doi.org/10.1053/j.gastro.2007.03.055
pmid: 17498512
|
125 |
Bhattacharjee J, Kirby M, Softic S, Miles L, Salazar-Gonzalez RM, Shivakumar P, Kohli R. Hepatic natural killer T-cell and CD8+ T-cell signatures in mice with nonalcoholic steatohepatitis. Hepatol Commun 2017; 1(4): 299–310
https://doi.org/10.1002/hep4.1041
pmid: 29152605
|
126 |
Henao-Mejia J, Elinav E, Jin C, Hao L, Mehal WZ, Strowig T, Thaiss CA, Kau AL, Eisenbarth SC, Jurczak MJ, Camporez JP, Shulman GI, Gordon JI, Hoffman HM, Flavell RA. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature 2012; 482(7384): 179–185
https://doi.org/10.1038/nature10809
pmid: 22297845
|
127 |
Hotamisligil GS. Inflammation and metabolic disorders. Nature 2006; 444(7121): 860–867
https://doi.org/10.1038/nature05485
pmid: 17167474
|
128 |
Brunt EM. Pathology of nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol 2010; 7(4): 195–203
https://doi.org/10.1038/nrgastro.2010.21
pmid: 20195271
|
129 |
Guebre-Xabier M, Yang S, Lin HZ, Schwenk R, Krzych U, Diehl AM. Altered hepatic lymphocyte subpopulations in obesity-related murine fatty livers: potential mechanism for sensitization to liver damage. Hepatology 2000; 31(3): 633–640
https://doi.org/10.1002/hep.510310313
pmid: 10706553
|
130 |
Li Z, Lin H, Yang S, Diehl AM. Murine leptin deficiency alters Kupffer cell production of cytokines that regulate the innate immune system. Gastroenterology 2002; 123(4): 1304–1310
https://doi.org/10.1053/gast.2002.35997
pmid: 12360490
|
131 |
Yang L, Jhaveri R, Huang J, Qi Y, Diehl AM. Endoplasmic reticulum stress, hepatocyte CD1d and NKT cell abnormalities in murine fatty livers. Lab Invest 2007; 87(9): 927–937
https://doi.org/10.1038/labinvest.3700603
pmid: 17607300
|
132 |
Tang ZH, Liang S, Potter J, Jiang X, Mao HQ, Li Z. Tim-3/galectin-9 regulate the homeostasis of hepatic NKT cells in a murine model of nonalcoholic fatty liver disease. J Immunol 2013; 190(4): 1788–1796
https://doi.org/10.4049/jimmunol.1202814
pmid: 23296703
|
133 |
Li Z, Soloski MJ, Diehl AM. Dietary factors alter hepatic innate immune system in mice with nonalcoholic fatty liver disease. Hepatology 2005; 42(4): 880–885
https://doi.org/10.1002/hep.20826
pmid: 16175608
|
134 |
Ma X, Hua J, Li Z. Probiotics improve high fat diet-induced hepatic steatosis and insulin resistance by increasing hepatic NKT cells. J Hepatol 2008; 49(5): 821–830
https://doi.org/10.1016/j.jhep.2008.05.025
pmid: 18674841
|
135 |
Kremer M, Hines IN, Milton RJ, Wheeler MD. Favored T helper 1 response in a mouse model of hepatosteatosis is associated with enhanced T cell-mediated hepatitis. Hepatology 2006; 44(1): 216–227
https://doi.org/10.1002/hep.21221
pmid: 16799967
|
136 |
Kremer M, Thomas E, Milton RJ, Perry AW, van Rooijen N, Wheeler MD, Zacks S, Fried M, Rippe RA, Hines IN. Kupffer cell and interleukin-12-dependent loss of natural killer T cells in hepatosteatosis. Hepatology 2010; 51(1): 130–141
https://doi.org/10.1002/hep.23292
pmid: 20034047
|
137 |
Li Z, Oben JA, Yang S, Lin H, Stafford EA, Soloski MJ, Thomas SA, Diehl AM. Norepinephrine regulates hepatic innate immune system in leptin-deficient mice with nonalcoholic steatohepatitis. Hepatology 2004; 40(2): 434–441
https://doi.org/10.1002/hep.20320
pmid: 15368448
|
138 |
Miyazaki Y, Iwabuchi K, Iwata D, Miyazaki A, Kon Y, Niino M, Kikuchi S, Yanagawa Y, Kaer LV, Sasaki H, Onoé K. Effect of high fat diet on NKT cell function and NKT cell-mediated regulation of Th1 responses. Scand J Immunol 2008; 67(3): 230–237
https://doi.org/10.1111/j.1365-3083.2007.02062.x
pmid: 18226013
|
139 |
Lynch L, Nowak M, Varghese B, Clark J, Hogan AE, Toxavidis V, Balk SP, O’Shea D, O’Farrelly C, Exley MA. Adipose tissue invariant NKT cells protect against diet-induced obesity and metabolic disorder through regulatory cytokine production. Immunity 2012; 37(3): 574–587
https://doi.org/10.1016/j.immuni.2012.06.016
pmid: 22981538
|
140 |
Elinav E, Pappo O, Sklair-Levy M, Margalit M, Shibolet O, Gomori M, Alper R, Thalenfeld B, Engelhardt D, Rabbani E, Ilan Y. Adoptive transfer of regulatory NKT lymphocytes ameliorates non-alcoholic steatohepatitis and glucose intolerance in ob/ob mice and is associated with intrahepatic CD8 trapping. J Pathol 2006; 209(1): 121–128
https://doi.org/10.1002/path.1950
pmid: 16482497
|
141 |
Wu L, Parekh VV, Gabriel CL, Bracy DP, Marks-Shulman PA, Tamboli RA, Kim S, Mendez-Fernandez YV, Besra GS, Lomenick JP, Williams B, Wasserman DH, Van Kaer L. Activation of invariant natural killer T cells by lipid excess promotes tissue inflammation, insulin resistance, and hepatic steatosis in obese mice. Proc Natl Acad Sci USA 2012; 109(19): E1143–E1152
https://doi.org/10.1073/pnas.1200498109
pmid: 22493234
|
142 |
Satoh M, Andoh Y, Clingan CS, Ogura H, Fujii S, Eshima K, Nakayama T, Taniguchi M, Hirata N, Ishimori N, Tsutsui H, Onoé K, Iwabuchi K. Type II NKT cells stimulate diet-induced obesity by mediating adipose tissue inflammation, steatohepatitis and insulin resistance. PLoS One 2012; 7(2): e30568
https://doi.org/10.1371/journal.pone.0030568
pmid: 22383967
|
143 |
Syn WK, Agboola KM, Swiderska M, Michelotti GA, Liaskou E, Pang H, Xie G, Philips G, Chan IS, Karaca GF, Pereira TA, Chen Y, Mi Z, Kuo PC, Choi SS, Guy CD, Abdelmalek MF, Diehl AM. NKT-associated hedgehog and osteopontin drive fibrogenesis in non-alcoholic fatty liver disease. Gut 2012; 61(9): 1323–1329
https://doi.org/10.1136/gutjnl-2011-301857
pmid: 22427237
|
144 |
Syn WK, Oo YH, Pereira TA, Karaca GF, Jung Y, Omenetti A, Witek RP, Choi SS, Guy CD, Fearing CM, Teaberry V, Pereira FE, Adams DH, Diehl AM. Accumulation of natural killer T cells in progressive nonalcoholic fatty liver disease. Hepatology 2010; 51(6): 1998–2007
https://doi.org/10.1002/hep.23599
pmid: 20512988
|
145 |
Wolf MJ, Adili A, Piotrowitz K, Abdullah Z, Boege Y, Stemmer K, Ringelhan M, Simonavicius N, Egger M, Wohlleber D, Lorentzen A, Einer C, Schulz S, Clavel T, Protzer U, Thiele C, Zischka H, Moch H, Tschöp M, Tumanov AV, Haller D, Unger K, Karin M, Kopf M, Knolle P, Weber A, Heikenwalder M. Metabolic activation of intrahepatic CD8+ T cells and NKT cells causes nonalcoholic steatohepatitis and liver cancer via cross-talk with hepatocytes. Cancer Cell 2014; 26(4): 549–564
https://doi.org/10.1016/j.ccell.2014.09.003
pmid: 25314080
|
146 |
Tajiri K, Shimizu Y, Tsuneyama K, Sugiyama T. Role of liver-infiltrating CD3+CD56+ natural killer T cells in the pathogenesis of nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol 2009; 21(6): 673–680
https://doi.org/10.1097/MEG.0b013e32831bc3d6
pmid: 19318971
|
147 |
Adler M, Taylor S, Okebugwu K, Yee H, Fielding C, Fielding G, Poles M. Intrahepatic natural killer T cell populations are increased in human hepatic steatosis. World J Gastroenterol 2011; 17(13): 1725–1731
https://doi.org/10.3748/wjg.v17.i13.1725
pmid: 21483633
|
148 |
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61(2): 69–90
https://doi.org/10.3322/caac.20107
pmid: 21296855
|
149 |
Li S, Ye L, Yu X, Xu B, Li K, Zhu X, Liu H, Wu X, Kong L. Hepatitis C virus NS4B induces unfolded protein response and endoplasmic reticulum overload response-dependent NF-κB activation. Virology 2009; 391(2): 257–264
https://doi.org/10.1016/j.virol.2009.06.039
pmid: 19628242
|
150 |
Hernaez R, El-Serag HB. Hepatocellular carcinoma surveillance: the road ahead. Hepatology 2017; 65(3): 771–773
https://doi.org/10.1002/hep.28983
pmid: 27943335
|
151 |
Miyagi T, Takehara T, Tatsumi T, Kanto T, Suzuki T, Jinushi M, Sugimoto Y, Sasaki Y, Hori M, Hayashi N. CD1d-mediated stimulation of natural killer T cells selectively activates hepatic natural killer cells to eliminate experimentally disseminated hepatoma cells in murine liver. Int J Cancer 2003; 106(1): 81–89
https://doi.org/10.1002/ijc.11163
pmid: 12794761
|
152 |
Margalit M, Shibolet O, Klein A, Elinav E, Alper R, Thalenfeld B, Engelhardt D, Rabbani E, Ilan Y. Suppression of hepatocellular carcinoma by transplantation of ex-vivo immune-modulated NKT lymphocytes. Int J Cancer 2005; 115(3): 443–449
https://doi.org/10.1002/ijc.20889
pmid: 15688366
|
153 |
Motohashi S, Nagato K, Kunii N, Yamamoto H, Yamasaki K, Okita K, Hanaoka H, Shimizu N, Suzuki M, Yoshino I, Taniguchi M, Fujisawa T, Nakayama T. A phase I-II study of α-galactosylceramide-pulsed IL-2/GM-CSF-cultured peripheral blood mononuclear cells in patients with advanced and recurrent non-small cell lung cancer. J Immunol 2009; 182(4): 2492–2501
https://doi.org/10.4049/jimmunol.0800126
pmid: 19201905
|
154 |
Ishikawa A, Motohashi S, Ishikawa E, Fuchida H, Higashino K, Otsuji M, Iizasa T, Nakayama T, Taniguchi M, Fujisawa T. A phase I study of α-galactosylceramide (KRN7000)-pulsed dendritic cells in patients with advanced and recurrent non-small cell lung cancer. Clin Cancer Res 2005; 11(5): 1910–1917
https://doi.org/10.1158/1078-0432.CCR-04-1453
pmid: 15756017
|
155 |
Yamasaki K, Horiguchi S, Kurosaki M, Kunii N, Nagato K, Hanaoka H, Shimizu N, Ueno N, Yamamoto S, Taniguchi M, Motohashi S, Nakayama T, Okamoto Y. Induction of NKT cell-specific immune responses in cancer tissues after NKT cell-targeted adoptive immunotherapy. Clin Immunol 2011; 138(3): 255–265
https://doi.org/10.1016/j.clim.2010.11.014
pmid: 21185787
|
156 |
Uchida T, Horiguchi S, Tanaka Y, Yamamoto H, Kunii N, Motohashi S, Taniguchi M, Nakayama T, Okamoto Y. Phase I study of α-galactosylceramide-pulsed antigen presenting cells administration to the nasal submucosa in unresectable or recurrent head and neck cancer. Cancer Immunol Immunother 2008; 57(3): 337–345
https://doi.org/10.1007/s00262-007-0373-5
pmid: 17690880
|
157 |
Giaccone G, Punt CJ, Ando Y, Ruijter R, Nishi N, Peters M, von Blomberg BM, Scheper RJ, van der Vliet HJ, van den Eertwegh AJ, Roelvink M, Beijnen J, Zwierzina H, Pinedo HM. A phase I study of the natural killer T-cell ligand α-galactosylceramide (KRN7000) in patients with solid tumors. Clin Cancer Res 2002; 8(12): 3702–3709
pmid: 12473579
|
158 |
Heczey A, Liu D, Tian G, Courtney AN, Wei J, Marinova E, Gao X, Guo L, Yvon E, Hicks J, Liu H, Dotti G, Metelitsa LS. Invariant NKT cells with chimeric antigen receptor provide a novel platform for safe and effective cancer immunotherapy. Blood 2014; 124(18): 2824–2833
https://doi.org/10.1182/blood-2013-11-541235
pmid: 25049283
|
159 |
Tian G, Courtney AN, Jena B, Heczey A, Liu D, Marinova E, Guo L, Xu X, Torikai H, Mo Q, Dotti G, Cooper LJ, Metelitsa LS. CD62L+ NKT cells have prolonged persistence and antitumor activity in vivo. J Clin Invest 2016; 126(6): 2341–2355
https://doi.org/10.1172/JCI83476
pmid: 27183388
|
160 |
Dhodapkar KM, Cirignano B, Chamian F, Zagzag D, Miller DC, Finlay JL, Steinman RM. Invariant natural killer T cells are preserved in patients with glioma and exhibit antitumor lytic activity following dendritic cell-mediated expansion. Int J Cancer 2004; 109(6): 893–899
https://doi.org/10.1002/ijc.20050
pmid: 15027123
|
161 |
Motohashi S, Kobayashi S, Ito T, Magara KK, Mikuni O, Kamada N, Iizasa T, Nakayama T, Fujisawa T, Taniguchi M. Preserved IFN-α production of circulating Vα24 NKT cells in primary lung cancer patients. Int J Cancer 2002; 102(2): 159–165
https://doi.org/10.1002/ijc.10678
pmid: 12385012
|
162 |
Motohashi S, Okamoto Y, Yoshino I, Nakayama T. Anti-tumor immune responses induced by iNKT cell-based immunotherapy for lung cancer and head and neck cancer. Clin Immunol 2011; 140(2): 167–176
https://doi.org/10.1016/j.clim.2011.01.009
pmid: 21349771
|
163 |
Xiao YS, Gao Q, Xu XN, Li YW, Ju MJ, Cai MY, Dai CX, Hu J, Qiu SJ, Zhou J, Fan J. Combination of intratumoral invariant natural killer T cells and interferon-γ is associated with prognosis of hepatocellular carcinoma after curative resection. PLoS One 2013; 8(8): e70345
https://doi.org/10.1371/journal.pone.0070345
pmid: 23940564
|
164 |
Bricard G, Cesson V, Devevre E, Bouzourene H, Barbey C, Rufer N, Im JS, Alves PM, Martinet O, Halkic N, Cerottini JC, Romero P, Porcelli SA, Macdonald HR, Speiser DE. Enrichment of human CD4+ Vα24/Vβ11 invariant NKT cells in intrahepatic malignant tumors. J Immunol 2009; 182(8): 5140–5151
https://doi.org/10.4049/jimmunol.0711086
pmid: 19342695
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
|
Shared |
|
|
|
|
|
Discussed |
|
|
|
|